American journal of translational research · 2026
Risk factors for cognitive dysfunction in prostate cancer patients undergoing androgen deprivation therapy: a retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Che Yu'nan, Yu Xinyang, Qiang Peng, Che Yafeng, Xu Gang, Lu Daofeng, Liu Xiaojie, Zhang Jinlan, Jiang Kun
Аннотация
OBJECTIVE: To evaluate the clinical efficacy of endocrine therapy for prostate cancer and analyze risk factors for treatment-related cognitive dysfunction.
METHODS: A retrospective study was conducted involving 100 prostate cancer patients receiving endocrine therapy and 100 non-recipients. Quality of life, urinary symptoms, and cognitive function were assessed. Patients were categorized into cognitive dysfunction (n=38) and non-dysfunction (n=62) groups based on post-treatment assessment. Univariate and multivariate analyses were used to identify influencing factors, and a predictive model was developed.
RESULTS: The endocrine therapy group showed significantly better quality of life and urinary symptom scores (all P < 0.05), though the 5-year survival rate was lower than that of the control group (72.4% vs 82.7%). Cognitive impairment incidence was 38%. Risk factors included older age, lower education, lower Montreal Cognitive Assessment (MoCA) scores, and higher Prostate-Specific Antigen (PSA), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS) scores (all P < 0.05). Multivariate analysis confirmed MoCA, age, SAS, and SDS as independent predictors. The predictive model demonstrated high discriminative ability (AUC=0.903).
CONCLUSION: Endocrine therapy improves quality of life and urinary symptoms in prostate cancer patients but is associated with cognitive dysfunction. A model incorporating MoCA, age, and psychological scores effectively predicts cognitive impairment risk, enabling targeted intervention.
METHODS: A retrospective study was conducted involving 100 prostate cancer patients receiving endocrine therapy and 100 non-recipients. Quality of life, urinary symptoms, and cognitive function were assessed. Patients were categorized into cognitive dysfunction (n=38) and non-dysfunction (n=62) groups based on post-treatment assessment. Univariate and multivariate analyses were used to identify influencing factors, and a predictive model was developed.
RESULTS: The endocrine therapy group showed significantly better quality of life and urinary symptom scores (all P < 0.05), though the 5-year survival rate was lower than that of the control group (72.4% vs 82.7%). Cognitive impairment incidence was 38%. Risk factors included older age, lower education, lower Montreal Cognitive Assessment (MoCA) scores, and higher Prostate-Specific Antigen (PSA), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS) scores (all P < 0.05). Multivariate analysis confirmed MoCA, age, SAS, and SDS as independent predictors. The predictive model demonstrated high discriminative ability (AUC=0.903).
CONCLUSION: Endocrine therapy improves quality of life and urinary symptoms in prostate cancer patients but is associated with cognitive dysfunction. A model incorporating MoCA, age, and psychological scores effectively predicts cognitive impairment risk, enabling targeted intervention.